Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Redmond

Showing results (161-170 of 205) with videos related to

Pageof 21
Sort By:
Human Pathology|April 1, 1994
c-erbB-2 amplification in breast cancer: detection in formalin-fixed, paraffin-embedded tissue by in situ hybridizationK L Smith, P D Robbins, H J Dawkins, et al.
Oncoimmunology|March 15, 2021
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunityElizabeth R Sturgill, Annah S Rolig, Stefanie N Linch, et al.
Plos One|August 13, 2013
The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumorMarka R Crittenden, Talicia Savage, Benjamin Cottam, et al.
Frontiers in Oncology|June 25, 2021
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 TherapyIsaac Kim, Venkatesh Rajamanickam, Brady Bernard, et al.
Biomedical Materials (Bristol, England)|January 25, 2014
The biocompatibility of silk fibroin and acellular collagen scaffolds for tissue engineering in the earYi Shen, Sharon L Redmond, John M Papadimitriou, et al.
Journal for Immunotherapy of Cancer|May 28, 2020
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8<sup>+</sup> T cell responses capable of curing multi-focal cancerJoshua M Walker, Annah S Rolig, Deborah H Charych, et al.
Oncoimmunology|May 13, 2026
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)Rachel E Sanborn, Shawn M Jensen, Christopher Paustian, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in miceMichael J Gough, Marka R Crittenden, MaryClare Sarff, et al.
ACS Biomaterials Science & Engineering|January 18, 2021
Enhancing Resistance of Silk Fibroin Material to Enzymatic Degradation by Cross-Linking Both Crystalline and Amorphous DomainsFilippo Valente, Benjamin J Allardyce, Matt S Hepburn, et al.
Oncogene|March 30, 2010
T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cellsK L Redmond, N T Crawford, H Farmer, et al.
Pageof 21

Showing results (161-170 of 205) with videos related to

Sort By:
Pageof 21
Human Pathology|April 1, 1994
c-erbB-2 amplification in breast cancer: detection in formalin-fixed, paraffin-embedded tissue by in situ hybridizationK L Smith, P D Robbins, H J Dawkins, et al.
Oncoimmunology|March 15, 2021
Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunityElizabeth R Sturgill, Annah S Rolig, Stefanie N Linch, et al.
Plos One|August 13, 2013
The peripheral myeloid expansion driven by murine cancer progression is reversed by radiation therapy of the tumorMarka R Crittenden, Talicia Savage, Benjamin Cottam, et al.
Frontiers in Oncology|June 25, 2021
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 TherapyIsaac Kim, Venkatesh Rajamanickam, Brady Bernard, et al.
Biomedical Materials (Bristol, England)|January 25, 2014
The biocompatibility of silk fibroin and acellular collagen scaffolds for tissue engineering in the earYi Shen, Sharon L Redmond, John M Papadimitriou, et al.
Journal for Immunotherapy of Cancer|May 28, 2020
NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8<sup>+</sup> T cell responses capable of curing multi-focal cancerJoshua M Walker, Annah S Rolig, Deborah H Charych, et al.
Oncoimmunology|May 13, 2026
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated advanced non-small cell lung cancer (NSCLC)Rachel E Sanborn, Shawn M Jensen, Christopher Paustian, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in miceMichael J Gough, Marka R Crittenden, MaryClare Sarff, et al.
ACS Biomaterials Science & Engineering|January 18, 2021
Enhancing Resistance of Silk Fibroin Material to Enzymatic Degradation by Cross-Linking Both Crystalline and Amorphous DomainsFilippo Valente, Benjamin J Allardyce, Matt S Hepburn, et al.
Oncogene|March 30, 2010
T-box 2 represses NDRG1 through an EGR1-dependent mechanism to drive the proliferation of breast cancer cellsK L Redmond, N T Crawford, H Farmer, et al.
Pageof 21